Please login to the form below
NICE
This page shows the latest NICE news and features for those working in and with pharma, biotech and healthcare.
NICE recommends Ultomiris for NHS use in patients with rare blood disorders
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Alexion’s long-acting C5 complement inhibitor Ultomiris for NHS use in patients with rare blood disorders. ... NICE has approved Ultomiris for the treatment of aHUS and
Latest news
-
NICE recommends Keytruda for colorectal cancer patients with rare mutations
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Keytruda for NHS use as a first-line treatment for colorectal cancer patients with rare mutations. ... As a result, NICE recommends that Keytruda treatment should be
-
NICE sets out plans for ‘ambitious’ five-year strategy
NICE refocuses on reducing health inequalities and accelerating access to the latest and most effective treatments. ... learning will bring digital health in disease prevention and self care to the fore,” said Sharmila Nebhrajani, NICE chair.
-
Alexion and NICE agree confidential discount for Ultomiris use on the NHS
NICE said clinical evidence shows Ultomiris is as effective and safe as Alexion's older PNH drug Soliris. ... Compared with Alexion’s older drug, Ultomiris is a cost-effective use of NHS resources, concluded NICE.
-
NICE rejects Keytruda for advanced bladder cancer in final guidance
Following this rejection, MSD appealed the decision, although NICE has upheld its previous guidance not to recommend Keytruda as a second-line treatment for advanced bladder cancer patients. ... In a statement issued today, NICE said that although
-
Novartis and NHS England reach ‘landmark’ deal for Zolgensma gene therapy for SMA
Following the deal, the National Institute for Health and Care Excellence ( NICE) published a draft recommendation for the gene therapy. ... NICE has agreed a managed access agreement for Zolgensma, meaning that further data is set to be collected prior
NICE recommends Keytruda for colorectal cancer patients with rare mutations
Novartis and NHS England reach ‘landmark’ deal for Zolgensma gene therapy for SMA
More from news
Approximately 400 fully matching, plus 830 partially matching documents found.
Latest Intelligence
-
Product launches: making the most of your one shot
Such platforms may have been viewed as a ‘nice to have’ option in the past.
-
Alzheimer’s disease: the search for a cure
Any new licensed drug would still need to be judged to be cost-effective by the National Institute of Care and Excellence (NICE).
-
Assessing the impact of disease prevalence on access and pricing of rare disease drugs in England
NICE uses CEA as the primary method for jointly assessing the clinical and economic impact of new drugs. ... This helps explain the non-linearity of the relationship between disease prevalence and AATC for ODs assessed by NICE.
-
Setting up for success in a post-Brexit, post-pandemic Britain
Recently, Galapagos and Gilead Sciences received a positive NICE recommendation for Jyseleca (filgotinib) for use on the NHS which, for the first time, will support access to an advanced therapy for ... With three COVID-19 vaccines approved for use in
-
The remote working revolution
It is a nice leveller because we are all just people trying to do the best we can in difficult circumstances.”.
Product launches: making the most of your one shot
Alzheimer’s disease: the search for a cure
Assessing the impact of disease prevalence on access and pricing of rare disease drugs in England
Setting up for success in a post-Brexit, post-pandemic Britain
The remote working revolution
More from intelligence
Approximately 12 fully matching, plus 128 partially matching documents found.
Latest appointments
-
NICE looks internally for new chief executive
He was appointed in April 1999 when NICE was first established under Tony Blair’s ‘New Labour’ government. ... I am delighted that Gill has been appointed as NICE’s next chief executive.
-
Professor Carole Longson moves from NICE to the ABPI
The Association of the British Pharmaceutical Industry (ABPI) has attracted Professor Carole Longson away from the National Institute for Health and Care Excellence (NICE) to be its new chief scientific officer, ... She most recently spent the 18 years
-
New health ministers and re-appointments after reshuffle
Freeman's role is also tied into the Department for Business, Innovation and Skills and includes expanded responsibility for the Cancer Drugs Fund, NICE and MHRA, research and development, issues around
-
Virgo Health Education appoints new senior team
She has over 15 years' experience working in medical education and is a member of the ISMPP Ethics Committee, the NICE Implementation External Reference Group and part of the Royal Berkshire
-
Former NICE chair Sir Michael Rawlins to lead MHRA
Care Excellence (NICE) from its formation in 1999 to his departure last year.
NICE looks internally for new chief executive
Professor Carole Longson moves from NICE to the ABPI
New health ministers and re-appointments after reshuffle
Virgo Health Education appoints new senior team
Former NICE chair Sir Michael Rawlins to lead MHRA
More from appointments
Approximately 4 fully matching, plus 10 partially matching documents found.
Latest from PMHub
-
Abbie's (associate copywriter) first 6-months at COUCH Health
Yet, it’s so nice that I’ve not felt disconnected from the company at all, considering most of my interaction with the team has been online.
-
Why it’s in everyone’s interest the Women’s Health Strategy for England succeeds
5. This strategy isn’t just a nice to have, a way for the Government to appeal to women voters.
-
WHITE PAPER: What's missing in women's health?
NHS. https://www.nhs.uk/conditions/menopause/. treatment/. Accessed December 23, 2019. 5. Menopause. NICE CKS. ... https://cks.nice.org.uk/menopause#! backgroundSub. Accessed January 6, 2020. 6. Harman C, Bower E.
-
Living with psoriasis: a patient perspective
ii] NICE Psoriasis Quality Standards Indicator. National Institute of Health and Care Excellence 2012.
-
Good design saves lives
Good design and creativity are vital to this process. This campaign by Fresenius Kabi is a nice illustration of these ideas in practice.
Abbie's (associate copywriter) first 6-months at COUCH Health
Why it’s in everyone’s interest the Women’s Health Strategy for England succeeds
WHITE PAPER: What's missing in women's health?
Living with psoriasis: a patient perspective
More from PMHub
Approximately 2 fully matching, plus 58 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Senior Account Manager
-
Salary TBC
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, Patient Engagement & Solutions, Lo...
-
Highly competitive salary
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
-
Planner
-
Salary TBC
- Group Account Director, Patient Engagement & Solutions, Lond...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
-
Publications Director
-
Competitive Salary
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO
- Merck signs $1.2bn supply deal with US government for Molnupiravir
- AZ, Pfizer/BioNTech COVID-19 vaccines 'highly effective' against Indian variant
- Sanofi’s C1s inhibitor sutimlimab hits the mark in late-stage CAD study
- Israel finds a ‘probable link’ between Pfizer vaccine and myocarditis cases
- Biogen, Sage’s depression therapeutic zuranolone hits primary endpoint in phase 3
- Your clinical trial participants are precious, so treat them as such
- Live Webinar: Helping Patients Become Active Participants in Their Own Care
- Top 10 ways that Medical Affairs teams can leverage the Impetus InSite Platform®
- The power of communication: Engaging diverse groups in healthcare
- US trial data shows Novavax’s COVID-19 vaccine is 90% effective
- Merck signs $1.2bn supply deal with US government for Molnupiravir
- Diversity and inclusion in clinical trials
- Nicky Hutchens appointed as deputy managing director at Four Health
- FDA approves Biogen’s aducanumab for Alzheimer’s disease in ‘landmark’ decision
- Lucid Group acquires US-based strategic brand consultants DiD
- Novo Nordisk says Victoza outperforms SGLT2 inhibitors
PMHub
EPG Health
REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical website. Support the...
Latest intelligence
- Top 10 ways that Medical Affairs teams can leverage the Impetus InSite Platform®
- Some of the most popular and innovative ways of using our cutting-edge asynchronous and synchronous virtual tools for Medical Affairs teams....
- The power of communication: Engaging diverse groups in healthcare
- Humans are diverse and communications to engage us need to be inclusive. It’s no longer about talking to a group, a cohort or an imagined section of society - especially...
- Building the hospital of the future
- Senior Consultant Leah Carlisle explores the growing trend of virtual hospitals and what it takes to develop a holistic digital ecosystem centered on the ultimate patient experience....
